Zoetis Inc. (ZTS)
The Schall Law Firm Begins A Probe Into Allegations Against Zoetis Inc And Invites Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Of Zoetis Inc With Losses Are Encouraged To Contact As The Schall Law Firm Initiates A Probe Into Claims
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis Inc Investors With Losses Are Urged To Reach Out As The Schall Law Firm Begins An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors With Losses Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Claims Against Zoetis Inc
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins A Probe Into Allegations Against Zoetis Inc And Urges Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investigation Into Claims Against Zoetis Inc Is Initiated By The Schall Law Firm And Investors Who Have Suffered Losses Are Encouraged To Contact
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Begins Investigation Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis Deep Dive: Better Setup Than Human Pharma
Zoetis is a leading animal pharmaceutical developer with 92% of sales from animal pharmaceuticals, over two-thirds of which are for pets. The company's competitive advantage lies in its R&D success, lower spending on R&D compared to human pharma, and a distribution network of unrivaled scale. Zoetis' growth is driven by pet humanization trends, but future success hinges on innovation and new drug releases, particularly the upcoming drug Librela.
The Schall Law Firm Commences Inquiry Into Claims Against Zoetis Inc And Invites Investors With Losses To Communicate
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Initiates Examination Of Accusations Against Zoetis Inc And Urges Investors With Losses To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Starts Probe Into Allegations Against Zoetis Inc And Encourages Investors With Losses To Contact
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis: Still A High Quality Business Led By Companion Animal Growth
Zoetis's stock has slumped in 2024, partly due to recent safety concerns regarding the company's arthritis drugs. Despite these safety concerns, Zoetis grew total revenue by 10% compared to Q1 2023 and raised their full-year 2024 revenue guidance. The company's companion animal products are supporting Zoetis's growth as the company sees a large opportunity with their osteoarthritis pain drugs.
